TransCode Therapeutics (NASDAQ:RNAZ) Receives “Buy” Rating from HC Wainwright

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $20.00 price target on the stock.

TransCode Therapeutics Trading Up 4.8 %

TransCode Therapeutics stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $66.33. The firm has a 50 day moving average price of $5.54 and a 200 day moving average price of $237.59.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.